Goal of the project
Current manufacturing protocols for adoptive T cell therapies, such as CAR-T and TCR-based approaches, are complex, costly, and time-consuming, limiting access for patients in need. In Norway alone, up to one-third of patients who begin the CAR-T process never receive their infusion due to manufacturing delays or rapid disease progression.
To address this, Dr. Lehander (Olweus group) and Dr. Kared (Munthe group) will combine their expertise to explore whether rapid activation of antigen-specific memory T cells can enable faster and more efficient transduction of therapeutic genes, potentially cutting manufacturing timelines significantly.
Grant details
- Awardee: Postdoc Madeleine Lehander, PhD, Olweus group.
- Title of project: Targeting Memory T Cells for Safer, Faster Adoptive Immunotherapy
- Collaborative groups: Olweus and Munthe
- Project participant: Hassen Kared, PhD, Munthe group.
- PRIMA Synergy Grant (08): 200 000 NOK
What you think of the grant mechanism?
"We are grateful for this grant, as it will allow us to explore innovative approaches to a key challenge in the field," says Madeleine. "It gives me the opportunity to develop a new line of research that builds on my core strengths, while broadening my expertise through the collaboration with Hassen."